{"id":6739,"date":"2025-11-18T12:00:49","date_gmt":"2025-11-18T12:00:49","guid":{"rendered":"https:\/\/blogs.luc.edu\/compliance\/?p=6739"},"modified":"2025-11-19T15:09:09","modified_gmt":"2025-11-19T15:09:09","slug":"beyond-weight-loss-how-ozempic-exposed-cracks-in-u-s-drug-compliance","status":"publish","type":"post","link":"https:\/\/blogs.luc.edu\/compliance\/?p=6739","title":{"rendered":"Beyond Weight Loss: How Ozempic Exposed Cracks in U.S. Drug Compliance"},"content":{"rendered":"

Nicole Polisar<\/span><\/i>\u00a0<\/span><\/p>\n

Associate Editor<\/span><\/i>\u00a0<\/span><\/p>\n

Loyola University Chicago School of Law, JD 2027<\/span><\/i>\u00a0<\/span><\/p>\n

A viral\u00a0weight-loss craze\u00a0that promised to trim waistlines\u00a0has become\u00a0one of the\u00a0most urgent compliance battles\u00a0for the U.S. Food and Drug Administration\u00a0(FDA). In early\u00a02025,\u00a0the FDA\u00a0uncovered\u00a0<\/span>counterfeit Ozempic<\/span><\/a>\u00a0circulating through unauthorized distributors and compounding pharmacies,\u00a0some\u00a0containing\u00a0unknown\u00a0ingredients that put patients at serious risk. The discovery exposed\u00a0the continued\u00a0fragility of\u00a0the nation\u2019s pharmaceutical supply chain, even after years of reform under the\u00a0<\/span>Drug Supply Chain Security Act (DSCSA)<\/span><\/a>. As demand for GLP-1 drugs like Ozempic and\u00a0Wegovy\u00a0skyrockets, regulatory gaps in manufacturing, compounding, and distribution have created\u00a0new avenues\u00a0for fraud, forcing the FDA to tighten enforcement and redefine the rules of pharmaceutical oversight.<\/span>\u00a0<\/span><\/p>\n

<\/p>\n

Drug compounding and counterfeits\u00a0<\/span><\/b>\u00a0<\/span><\/p>\n

Ozempic<\/span><\/a>,\u00a0and similar drugs,\u00a0were originally developed for Type 2 diabetes, but their success in promoting weight loss\u00a0has\u00a0turned them into cultural phenomena.\u00a0The GLP-1 boom has produced a convergence of market forces: astronomical consumer demand, aggressive online marketing, and inconsistent regulatory enforcement.\u00a0As a result,\u00a0<\/span>manufacturer shortages arose<\/span><\/a>\u00a0for the\u00a0drug\u2019s\u00a0delivery\u00a0mechanism,\u00a0but\u00a0the active\u00a0ingredient\u00a0\u2013\u00a0semaglutide\u00a0\u2013\u00a0was still plentiful.\u00a0Under sections\u00a0503A and 503B of the\u00a0<\/span>Food Drug & Cosmetic Act (FD&C Act)<\/span><\/a>, companies\u00a0can\u00a0create compound drugs for medications that are not commercially available, such as\u00a0when a medication is on the FDA\u2019s drug shortages list.\u00a0<\/span>Drug compounding<\/span><\/a>\u00a0is\u00a0the process of creating customized medications by\u00a0mixing\u00a0or altering\u00a0the ingredients of a drug\u00a0to meet the specific needs of an individual patient. Compounded drugs are\u00a0<\/span>not\u00a0approved<\/span><\/a> by the FDA, so their safety, effectiveness, and quality are not verified, which\u00a0can\u00a0put\u00a0consumers at risk.\u00a0<\/span>\u00a0<\/span><\/p>\n

In 2022, the FDA put Ozempic and Wegovy on its\u00a0<\/span>drug shortages list.<\/span><\/a> This temporarily allowed compounding pharmacies to create semaglutide formulations. In February 2025, the FDA announced that the <\/span>shortage was resolved<\/span><\/a>\u00a0and required pharmacies to phase out compounded semaglutide injectables. Once supply stabilized, compounding these drugs without explicit FDA approval became illegal.\u00a0However, many compounders continued doing so, either unaware of the policy shift or deliberately ignoring it to meet consumer demand.\u00a0On April 3,\u00a0<\/span>Novo Nordisk<\/span><\/a>, the makers of Ozempic and\u00a0Wegovy,\u00a0informed the FDA that\u00a0hundreds of\u00a0<\/span>counterfeit\u00a0GLP-1<\/span><\/a>\u00a0injectables\u00a0were in the U.S. drug supply chain.\u00a0As with other compounded drugs, these counterfeit injectables\u00a0are not properly regulated\u00a0and can cause\u00a0<\/span>harm to patients<\/span><\/a> due to incorrect dosing, inclusion of dangerous ingredients, or a complete lack of the active ingredient.\u00a0 <\/span>\u00a0<\/span><\/p>\n

DSCSA was intended to prevent this scenario.\u00a0<\/span>DSCSA<\/span><\/a>\u00a0amended\u00a0the FD&C Act\u00a0by\u00a0providing a\u00a0framework\u00a0for\u00a0unit-level\u00a0electronic\u00a0tracking and tracing\u00a0of\u00a0prescription drugs.\u00a0DSCSA\u2019s\u00a0<\/span>purpose<\/span><\/a>\u00a0is to\u00a0enhance the security of the pharmaceutical supply chain\u00a0by authenticating products across every handoff in the supply chain and\u00a0eliminating\u00a0opportunities for counterfeit entry.\u00a0Yet, the Ozempic episode revealed that many\u00a0<\/span>smaller distributors<\/span><\/a>\u00a0and pharmacies still\u00a0lack\u00a0compliant tracking systems, allowing illegitimate products to blend with legitimate ones.<\/span>\u00a0<\/span><\/p>\n

FDA\u2019s\u00a0escalating\u00a0response<\/span><\/b>\u00a0<\/span><\/p>\n

The agency\u2019s post-Ozempic strategy signals a tougher era of pharmaceutical enforcement.\u00a0The FDA issued\u00a0an\u00a0<\/span>import alert<\/span><\/a>\u00a0permitting detention without physical examination (DWPE) of suspect drug shipments at U.S. entry points. Under this authority, the agency\u00a0<\/span>may hold products<\/span><\/a>\u00a0that\u00a0appear\u00a0non-compliant with federal drug standards pending verification. Importers bear the burden of proving quality assurance and compliance before the products are cleared for distribution. Additionally, recent\u00a0<\/span>warning letters<\/span><\/a>\u00a0target clinics\u00a0promoting\u00a0\u201ccustom\u201d GLP-1 cocktails and\u00a0online pharmacies selling unverified vials. The FDA has also urged healthcare providers to verify all National Drug Codes (NDCs), confirm authorized distributors, and report suspect products\u00a0immediately.<\/span>\u00a0<\/span><\/p>\n

Beyond enforcement, the Ozempic case has prompted renewed focus on supply-chain\u00a0<\/span>interoperability<\/span><\/a>, which is\u00a0DSCSA\u2019s final implementation stage\u00a0and\u00a0requires electronic tracing across manufacturers, wholesalers, and dispensers. According to the FDA, many entities\u00a0<\/span>missed the 2023 compliance<\/span><\/a>\u00a0deadline\u00a0and\u00a0continue to rely on fragmented or incompatible verification tools. For\u00a0<\/span>smaller distributors<\/span><\/a>, the cost of upgrading software and harmonizing data standards has proven especially burdensome.\u00a0The counterfeit incident may accelerate that transition, as liability for distributing falsified products increasingly falls on every participant in the chain.<\/span>\u00a0<\/span><\/p>\n

Looking ahead<\/span><\/b>\u00a0<\/span><\/p>\n

The FDA\u2019s crackdown on counterfeit GLP-1s may mark the beginning of a broader shift in regulatory philosophy: from reactive enforcement to\u00a0<\/span>predictive compliance<\/span><\/a>, where real-time data sharing and supply-chain analytics\u00a0identify\u00a0risk before harm occurs. But achieving that goal requires\u00a0<\/span>coordination<\/span><\/a> across regulators, manufacturers, and technology providers \u2014 something DSCSA envisioned but has yet to fully deliver. Until then, Ozempic\u2019s legacy may extend far beyond weight loss. It will be remembered as the drug that revealed the fragile boundary between scientific innovation and regulatory failure, and how the race for results can sometimes outpace the rules meant to protect us.<\/span>\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

A viral weight-loss craze that promised to trim waistlines has become one of the most urgent compliance battles for the U.S. Food and Drug Administration (FDA). In early 2025, the FDA uncovered counterfeit Ozempic circulating through unauthorized distributors and compounding pharmacies, some containing unknown ingredients that put patients at serious risk. The discovery exposed the continued fragility of the nation\u2019s pharmaceutical supply chain, even after years of reform under the Drug Supply Chain Security Act (DSCSA). As demand for GLP-1 drugs like Ozempic and Wegovy skyrockets, regulatory gaps in manufacturing, compounding, and distribution have created new avenues for fraud, forcing the FDA to tighten enforcement and redefine the rules of pharmaceutical oversight. <\/p>\n","protected":false},"author":188,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[2423,1014,1205,2421,1571,2422],"class_list":["post-6739","post","type-post","status-publish","format-standard","hentry","category-fda","tag-dscsa","tag-healthcare","tag-journal-of-regulatory-compliance","tag-ozempic","tag-pharmaceuticals","tag-wegovy"],"_links":{"self":[{"href":"https:\/\/blogs.luc.edu\/compliance\/index.php?rest_route=\/wp\/v2\/posts\/6739","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.luc.edu\/compliance\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.luc.edu\/compliance\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.luc.edu\/compliance\/index.php?rest_route=\/wp\/v2\/users\/188"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.luc.edu\/compliance\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6739"}],"version-history":[{"count":3,"href":"https:\/\/blogs.luc.edu\/compliance\/index.php?rest_route=\/wp\/v2\/posts\/6739\/revisions"}],"predecessor-version":[{"id":6742,"href":"https:\/\/blogs.luc.edu\/compliance\/index.php?rest_route=\/wp\/v2\/posts\/6739\/revisions\/6742"}],"wp:attachment":[{"href":"https:\/\/blogs.luc.edu\/compliance\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6739"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.luc.edu\/compliance\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6739"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.luc.edu\/compliance\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6739"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}